Artiva Biotherapeutics (ARTV) 10% Owner RA Capital Buys Stock

What Happened
RA Capital Management, L.P. (reported as a 10% owner) purchased 41,319 shares of Artiva Biotherapeutics (ARTV) on 2026-07-24. The weighted-average reported price was $9.99 per share, for a total transaction value of approximately $412,777. This was a purchase transaction (code P), which is generally viewed as a bullish signal compared with routine selling.

Key Details

• Transaction date: 2026-07-24; filing date (Form 4): 2026-07-28 — filing appears timely.
• Price: weighted average $9.99; purchases occurred at prices ranging $9.96–$10.00 (footnote F1).
• Shares acquired: 41,319; total ≈ $412,777.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: RA Capital is the investment manager for several funds/accounts (F2) and disclaims beneficial ownership except to the extent of pecuniary interest; purchases were held directly by one or more managed vehicles per F3–F6. Laura Stoppel, a Partner of the Adviser, serves on Artiva’s board of directors (remark).

Context
This is institutional buying by a reported 10% owner (an investment manager and its funds/accounts), not an individual executive. The filing notes the purchase was executed in multiple transactions at slightly different prices (F1). For retail investors, purchases by large shareholders can be informative, but they reflect fund-level decisions and allocation among managed vehicles rather than a personal executive stake.